Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Diagnostics (Basel) ; 14(11)2024 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-38893674

RESUMEN

The study aimed to assess the prevalence of COVID-19 and Klebsiella spp. coinfection across continents. Conducted following PRISMA guidelines, a systematic review utilized PubMed, Embase, SCOPUS, ScienceDirect, and Web of Science databases, searching for literature in English published from December 2019 to December 2022, using specific Health Sciences descriptors. A total of 408 records were identified, but only 50 were eligible, and of these, only 33 were included. Thirty-three references were analyzed to evaluate the correlation between COVID-19 and Klebsiella spp. infections. The tabulated data represented a sample group of 8741 coinfected patients. The findings revealed notable disparities in co-infection rates across continents. In Asia, 23% of individuals were infected with Klebsiella pneumoniae, while in Europe, the proportion of co-infected patients stood at 15%. Strikingly, on the African continent, 43% were found to be infected with Klebsiella pneumoniae, highlighting significant regional variations. Overall, the proportion of Klebsiella pneumoniae co-infections among COVID-positive individuals were determined to be 19%. Particularly concerning was the observation that 1 in 6 ICU coinfections was attributed to Klebsiella pneumoniae, indicating its substantial impact on patient outcomes and healthcare burden. The study underscores the alarming prevalence of co-infection between COVID-19 and Klebsiella pneumoniae, potentially exacerbating the clinical severity of patients and posing challenges to treatment strategies. These findings emphasize the importance of vigilant surveillance and targeted interventions to mitigate the adverse effects of bacterial coinfections in the context of the COVID-19 pandemic.

2.
Materials (Basel) ; 15(4)2022 Feb 10.
Artículo en Inglés | MEDLINE | ID: mdl-35207837

RESUMEN

Polymeric membranes are a viable and sustainable option for the biotechnology industry from an economic and environmental point of view. In this study, we evaluated tissue response and tolerance to the implantation of a polymeric membrane prepared with cashew gum polysaccharide (CGP) associated with polyvinyl alcohol (PVA). The objective was to characterize the biocompatibility of the CGP/PVA membrane in vivo. Following the evaluation criteria of the ISO 10993-6 standard, we demonstrated that the CGP/PVA membrane showed moderate tissue reaction, with a non-irritating ISO pattern, a thinner fibrous capsule, and a smaller amount of collagen compared to the positive control group. At 30 and 60 days, the membrane presented a similar amount of mast cells to that observed in the negative control group. The data demonstrate that the CGP/PVA membrane presents biocompatibility in accordance with the ISO 10993-6 standard.

3.
Eur J Pharm Sci ; 150: 105330, 2020 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-32268198

RESUMEN

The aim of this work was to prepare chitosan nanoparticles containing insulin and to evaluate its therapeutic activity during wound healing in diabetic rats. The hypothesis that guided this study was that the combination of insulin within chitosan nanoparticles could stimulate the signaling pathway for wound healing. The chitosan nanoparticles were prepared by the ionotropic gelation method presenting average size of 183.3 ± 8.32 nm, polydispersity index (PDI) 0.397 ± 0.07 and zeta potential of 33.7 ± 2.45 mV for empty chitosan nanoparticles (EC) and 245.9 ± 25.46 nm and PDI 0.463 ± 0.01, and zeta potential of 39.3 ± 4.88 mV for chitosan nanoparticles containing insulin (IC). The insulin association efficiency was 97.19% ± 2.18. These nanoparticles and free insulin (FI) were incorporated within a hydrogel (Sepigel®) for topical application in the wound of 72 diabetic rats distributed in four groups: Sepigel® (S, control), free insulin (FI), empty chitosan nanoparticles (EC), and chitosan nanoparticles containing insulin (IC). The animals in each group were reorganized into three subgroups (n = 6) to assess their clinical signs after days 3, 7, and 14 from the beginning of treatments. Intense fibroplasias were observed in the free or insulin-chitosan nanoparticles groups. In the latter, a large number of blood vessels were observed at day 7th. Our data indicated that both empty and insulin-containing chitosan nanoparticles were able to stimulate inflammatory cell proliferation, and angiogenesis, followed by wound maturation.


Asunto(s)
Quitosano/administración & dosificación , Diabetes Mellitus Experimental/tratamiento farmacológico , Portadores de Fármacos/administración & dosificación , Hipoglucemiantes/administración & dosificación , Insulina/administración & dosificación , Nanopartículas/administración & dosificación , Cicatrización de Heridas/efectos de los fármacos , Animales , Femenino , Ratas Wistar , Piel/efectos de los fármacos , Piel/lesiones , Piel/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...